Results from the Phase III FIRST (MM-020/IFM 07-01) trial, published in the New England Journal of Medicine, have demonstrated that continuous treatment with Revlimid® and low-dose dexamethasone, given until disease progression, improved progression-free survival and overall survival in newly diagnosed transplant-ineligible myeloma patients compared to those receiving a fixed period (72 weeks) of the same treatment or standard melphalan, prednisolone and thalidomide. Based on these data, Revlimid in combination with dexamethasone has been submitted for the treatment of newly diagnosed myeloma patients with the respective regulatory authorities in Europe and the US. Decisions are expected in 2015.

Read full article